Hypomethylators Are Safe and Effective in MPNs

The hypomethylating agents decitabine and azacitidine administered at a low dose are safe and effective for patients with lower-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN), according to results of a recent study published in Blood.

 Oncology Newswatch

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.